UBE3A
UBE3A (ubiquitin protein ligase E3A, also known as E6-AP, AS, ANCR, EPVE6AP and HPVE6A) is an E3 ubiquitin-protein ligase of the HECT domain family. It forms part of the ubiquitin protein degradation system and is linked to Angelman syndrome and to human papillomavirus oncogenesis. Browse Assay Genie's current range of UBE3A research reagents below, or read on for the biology behind the target.
UBE3A is an E3 ubiquitin-protein ligase and part of the ubiquitin protein degradation system, in which E3 enzymes direct the attachment of ubiquitin to substrate proteins. In the context of viral infection, UBE3A catalyses ubiquitination of p53 (TP53) that is mediated by the E6 protein of high-risk human papillomavirus. This activity contributes to the neoplastic progression of cells infected by these viruses. NCBI Gene notes that the protein interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumour protein p53.
The UBE3A gene belongs to the HECT domain E3 ubiquitin protein ligases group and the protein is annotated as localising to the cytoplasm and the nucleus. The gene is imprinted: it is maternally expressed in brain and biallelically expressed in other tissues. Alternative splicing gives three transcript variants that encode three isoforms with different N-termini, and further transcript variants have been described whose full-length nature has not been determined. A mouse ortholog, Ube3a, is recognised.
The protein was originally named for its association with papillomavirus, and the previous HGNC name is human papilloma virus E6-associated protein, which is the origin of the alias E6-AP. Its disease relevance extends beyond virology. Maternally inherited deletion of the gene causes Angelman syndrome, characterised by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech and characteristic facies. UBE3A research therefore spans ubiquitin biology, neurodevelopment and virus-driven cancer.
Maternally inherited deletion of the UBE3A gene causes Angelman syndrome, making the protein central to studies of this neurodevelopmental disorder.
UBE3A is an E3 ligase within the ubiquitin protein degradation system, so it is studied for how substrates are selected for ubiquitination.
UBE3A mediates E6-dependent ubiquitination of p53, contributing to neoplastic progression in cells infected by high-risk papillomavirus.
UBE3A is maternally expressed in brain yet biallelically expressed in other tissues, offering a model for tissue-specific imprinting.
UBE3A is an E3 ubiquitin-protein ligase that acts within the ubiquitin protein degradation system. In cells infected with high-risk human papillomavirus, it catalyses E6-mediated ubiquitination of p53, which contributes to neoplastic progression. Check the datasheet of any product for its validated reactivity.
UBE3A is also called E6-AP, AS, ANCR, EPVE6AP, HPVE6A and FLJ26981. Its former HGNC name was human papilloma virus E6-associated protein. Alternative splicing produces three transcript variants encoding three isoforms that differ in their N-termini.
Maternally inherited deletion of the UBE3A gene causes Angelman syndrome, a disorder with severe motor and intellectual impairment, epilepsy and absence of speech. The protein is also exploited by human papillomavirus types 16 and 18 E6 to drive p53 degradation. The mouse ortholog is Ube3a.
Other ubiquitin-conjugating enzymes and ubiquitination pathway proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q05086; product specifications from Assay Genie datasheets.